Source:http://linkedlifedata.com/resource/pubmed/id/14676677
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-12-16
|
| pubmed:abstractText |
Acute hypotension, hypoxemia, cardiac arrhythmias, cardiac arrest, (or a combination of these), and sudden death are well-recognized complications of the cemented hip arthroplasty procedure. Collectively, these are known as the bone cement implantation syndrome (BCIS). The endogenous cannabinoids, anandamide (ANA) and 2-arachidonylglycerol (2-AG), are reported to be strong vasodilators and play a role in the hypotension associated with hemorrhagic and septic shock. In the present study, a potential role for the endogenous cannabinoids in influencing hemodynamic variables in BCIS was investigated. Thirty-five patients (35 hips) entered a prospective, randomized clinical trial. The patients were divided into two groups. Group 1 comprised 16 patients who had the component inserted using a conventional cementing technique, whereas group 2 consisted of 19 patients who had the femoral component inserted without cement. Blood samples were taken at six consecutive time points: before anesthesia, after reaming the femur, 2 min after insertion of stems with or without cement into the femur, and 10 min, 20, and 30 min after stem insertion. In group 1 (with cement), the mean levels of ANA and 2-AG significantly increased after stem insertion. In a comparison of each group after stem insertion, mean ANA and 2-AG levels in group 1 also significantly differed from those in group 2. By contrast, in group 2 (without cement) neither ANA nor 2-AG levels exhibited a significant increase or change at any point in time. In conclusion, we have shown for the first time that endogenous cannabinoids are candidates for lipid mediators of BCIS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-arachidonylglycerol,
http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Cements,
http://linkedlifedata.com/resource/pubmed/chemical/Cannabinoids,
http://linkedlifedata.com/resource/pubmed/chemical/Glycerides,
http://linkedlifedata.com/resource/pubmed/chemical/Polyunsaturated Alkamides,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/anandamide
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1073-2322
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
8-12
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14676677-Aged,
pubmed-meshheading:14676677-Arachidonic Acids,
pubmed-meshheading:14676677-Arthroplasty, Replacement, Hip,
pubmed-meshheading:14676677-Blood Pressure,
pubmed-meshheading:14676677-Bone Cements,
pubmed-meshheading:14676677-Cannabinoids,
pubmed-meshheading:14676677-Female,
pubmed-meshheading:14676677-Glycerides,
pubmed-meshheading:14676677-Heart Diseases,
pubmed-meshheading:14676677-Humans,
pubmed-meshheading:14676677-Hypotension,
pubmed-meshheading:14676677-Lipid Metabolism,
pubmed-meshheading:14676677-Male,
pubmed-meshheading:14676677-Models, Biological,
pubmed-meshheading:14676677-Polyunsaturated Alkamides,
pubmed-meshheading:14676677-Prospective Studies,
pubmed-meshheading:14676677-Prosthesis Failure,
pubmed-meshheading:14676677-Shock,
pubmed-meshheading:14676677-Syndrome,
pubmed-meshheading:14676677-Time Factors,
pubmed-meshheading:14676677-Vasodilator Agents
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome.
|
| pubmed:affiliation |
Department of Orthopaedic Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|